Ark Invest Expands Positions in Amazon, 3D Systems, and CRISPR Therapeutics

Ark Invest, led by CEO Cathie Wood, has increased its holdings in Amazon (AMZN), 3D Systems (DDD), and CRISPR Therapeutics (CRSP). The transactions, disclosed in the fund's daily trade logs, signal a strategic reinvestment in high-growth sectors across e-commerce, healthcare, and industrial tech. The increase in Amazon shares comes ahead of the company's third-quarter financial report scheduled for October 31. While the stock is currently trading within 6% of its July all-time highs, Wood is betting on a stronger performance than the previous quarter, where a 10% revenue increase led to a 9% share price drop following the report. Wall Street analysts are forecasting net sales for Amazon of $157.2 billion, representing an 11% increase. Expectations for the bottom line are more aggressive, with analysts projecting a 33% jump in earnings per share, supported by the high-margin Amazon Web Services (AWS) cloud computing division. Beyond the e-commerce giant, Ark has added to its positions in 3D Systems and CRISPR Therapeutics. 3D Systems has struggled significantly in 2024, with its stock price falling by more than half and revenue declining for three consecutive years, despite recent FDA clearances for a jetted denture solution and a total ankle prosthesis. CRISPR Therapeutics remains a core bet on the future of gene editing. With a market capitalization exceeding $4 billion—nearly half of which is backed by liquidity on its balance sheet—the company is now attempting to expand its reach from sickle cell disease treatments into the larger oncology and cardiovascular markets.